It is one of the most common conversations in GLP-1 communities right now. Someone decides to stop — because of the cost, the side effects, a shortage, or simply because they have hit their goal and want to see whether they can maintain it alone. Then comes the question nobody fully prepares for: what happens to my body when I do?
The clinical trial answer is stark. The STEP 1 trial extension, published in Diabetes, Obesity and Metabolism in 2022, tracked participants for a full year after they stopped semaglutide. One year after withdrawal, participants regained two-thirds of their prior weight loss, with similar reversals in cardiometabolic improvements. Blood pressure, blood sugar markers and cholesterol — all of which had improved during treatment — largely returned toward their starting points. The researchers’ conclusion was direct: these findings confirm the chronic nature of obesity and suggest ongoing treatment is required to maintain results.
That is the trial data. But real-world data tells a more complicated story.
A large analysis from Epic Research, drawing on records from over 300 million patients across 1,700 US hospitals, found that at 24 months post-cessation, 56% of semaglutide patients either maintained their weight loss or lost additional weight. Complete weight regain occurred in only 23% of semaglutide users by the two-year mark. Weight trajectories appeared to stabilise after the first 12 months — suggesting that the year after stopping is the critical window.
Why the gap between trials and reality? Real-world patients often make lasting changes to diet and exercise during treatment that continue after stopping. Real-world stopping is also rarely abrupt — gradual dose reduction, lifestyle habits and ongoing medical contact all influence the outcome.
What does this mean in practice? Stopping is not a cliff edge for everyone. But the biology is real: without the medication, appetite suppression reduces. The evidence is clear that the first six to twelve months after stopping require active attention — and patients who plan for that window, rather than being surprised by it, do significantly better.
Sources
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725
- Epic Research. Two years after stopping GLP-1s, most patients sustain at least some weight loss. September 2025. epicresearch.org
- Gasoyan H et al. Weight trajectories after last tirzepatide or semaglutide prescription across a federated health network. medRxiv. 2026. doi:10.64898/2026.01.26.26344839